Literature DB >> 30830974

Multicentre study of multidisciplinary team assessment of pancreatic cancer resectability and treatment allocation.

J Kirkegård1, E K Aahlin2, M Al-Saiddi3, S O Bratlie4, M Coolsen5, R J de Haas6, M den Dulk5,7, C Fristrup8, E M Harrison9, M B Mortensen8, M W Nijkamp10, J Persson4, J A Søreide11,12, S J Wigmore9, T Wik13, F V Mortensen1.   

Abstract

BACKGROUND: Multidisciplinary team (MDT) meetings have been adopted widely to ensure optimal treatment for patients with cancer. Agreements in tumour staging, resectability assessments and treatment allocation between different MDTs were assessed.
METHODS: Of all patients referred to one hospital, 19 patients considered to have non-metastatic pancreatic cancer for evaluation were selected randomly for a multicentre study of MDT decisions in seven units across Northern Europe. Anonymized clinical information and radiological images were disseminated to the MDTs. All patients were reviewed by the MDTs for radiological T, N and M category, resectability assessment and treatment allocation. Each MDT was blinded to the decisions of other teams. Agreements were expressed as raw percentages and Krippendorff's α values, both with 95 per cent confidence intervals.
RESULTS: A total of 132 evaluations in 19 patients were carried out by the seven MDTs (1 evaluation was excluded owing to technical problems). The level of agreement for T, N and M categories ranged from moderate to near perfect (46·8, 61·1 and 82·8 per cent respectively), but there was substantial variation in assessment of resectability; seven patients were considered to be resectable by one MDT but unresectable by another. The MDTs all agreed on either a curative or palliative strategy in less than half of the patients (9 of 19). Only fair agreement in treatment allocation was observed (Krippendorff's α 0·31, 95 per cent c.i. 0·16 to 0·45). There was a high level of agreement in treatment allocation where resectability assessments were concordant.
CONCLUSION: Considerable disparities in MDT evaluations of patients with pancreatic cancer exist, including substantial variation in resectability assessments.
© 2019 BJS Society Ltd Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2019        PMID: 30830974     DOI: 10.1002/bjs.11093

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  9 in total

1.  Anatomic Criteria Determine Resectability in Locally Advanced Pancreatic Cancer.

Authors:  Georgios Gemenetzis; Alex B Blair; Minako Nagai; William R Burns; Christopher L Wolfgang; Jin He; Vincent P Groot; Ding Ding; Ammar A Javed; Richard A Burkhart; Elliot K Fishman; Ralph H Hruban; Matthew J Weiss; John L Cameron; Amol Narang; Daniel Laheru; Kelly Lafaro; Joseph M Herman; Lei Zheng
Journal:  Ann Surg Oncol       Date:  2021-08-27       Impact factor: 5.344

2.  Treatment Inequity: Examining the Influence of Non-Hispanic Black Race and Ethnicity on Pancreatic Cancer Care and Survival in Wisconsin.

Authors:  Andrea M Schiefelbein; John K Krebsbach; Amy K Taylor; Jienian Zhang; Chloe E Haimson; Amy Trentham-Dietz; Melissa C Skala; John M Eason; Sharon M Weber; Patrick R Varley; Syed N Zafar; Noelle K LoConte
Journal:  WMJ       Date:  2022-07

3.  Heterogeneity in neoadjuvant therapy for localized pancreatic cancer: a persisting radiant autonomy.

Authors:  Kjetil Søreide
Journal:  Hepatobiliary Surg Nutr       Date:  2021-04       Impact factor: 7.293

4.  Surgical Management of Non-Metastatic Pancreatic Cancer in the United Kingdom: Results of a Nationwide Survey on Current Practice.

Authors:  Georgios Gemenetzis; Siobhan McKay; Samir Pathak; John Moir; Richard Laing; Nigel B Jamieson; Alastair L Young; Nikolaos A Chatzizacharias; Francesco Giovinazzo; Keith J Roberts
Journal:  Front Oncol       Date:  2021-12-23       Impact factor: 6.244

5.  Geographic variation in attitudes regarding management of locally advanced pancreatic cancer.

Authors:  Logan R McNeil; Alex B Blair; Robert W Krell; Chunmeng Zhang; Aslam Ejaz; Vincent P Groot; Georgios Gemenetzis; James C Padussis; Massimo Falconi; Christopher L Wolfgang; Matthew J Weiss; Chandrakanth Are; Jin He; Bradley N Reames
Journal:  Surg Open Sci       Date:  2022-08-06

Review 6.  Value and Quality of Care in Head and Neck Oncology.

Authors:  Robert P Takes; Gyorgy B Halmos; John A Ridge; Paolo Bossi; Matthias A W Merkx; Alessandra Rinaldo; Alvaro Sanabria; Ludi E Smeele; Antti A Mäkitie; Alfio Ferlito
Journal:  Curr Oncol Rep       Date:  2020-07-10       Impact factor: 5.075

Review 7.  Conversion Surgery for Advanced Pancreatic Cancer.

Authors:  Thomas Hank; Oliver Strobel
Journal:  J Clin Med       Date:  2019-11-12       Impact factor: 4.241

8.  Impact of Borderline Resectability in Pancreatic Head Cancer on Patient Survival: Biology Matters According to the New International Consensus Criteria.

Authors:  Casper van Eijck; Stefan Löb; Friedrich Anger; Anna Döring; Jacob van Dam; Johan Friso Lock; Ingo Klein; Max Bittrich; Christoph-Thomas Germer; Armin Wiegering; Volker Kunzmann
Journal:  Ann Surg Oncol       Date:  2020-09-12       Impact factor: 5.344

Review 9.  [Surgery for periampullary pancreatic cancer].

Authors:  Thomas Hank; Ulla Klaiber; Klaus Sahora; Martin Schindl; Oliver Strobel
Journal:  Chirurg       Date:  2021-07-14       Impact factor: 0.955

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.